Dolasetron

Drug Profile

Dolasetron

Alternative Names: Anemet; Anzemet; MDL 73147EF

Latest Information Update: 24 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Antiemetics; Antipsychotics; Indoles; Quinolizines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Nausea and vomiting
  • Discontinued Psychotic disorders

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 07 Mar 2008 Discontinued - Phase-III for Psychotic disorders in European Union (unspecified route)
  • 05 Dec 2005 Dolasetron has been licensed to Organon in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top